IP Library Granted Patent US 9,487,518
Granted Patent B2
US 9,487,518 · App. 13/410,779 · Granted Nov 8, 2016

HIV inhibiting bicyclic pyrimidine derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,487,518
App. No.
13/410,779
Granted
Nov 8, 2016
Kind
B2
Abstract

HIV replication inhibitors of formula wherein -a 1 =a 2 -a 3 =a 4 - is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b 1 =b 2 -b 3 =b 4 - is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; n and m is 0-4, R 1 is hydrogen; aryl; formyl; C 1-6 alkylcarbonyl; C 1-6 alkyl; C 1-6 alkyloxycarbonyl; R 2 is OH; halo; C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; substituted carbonyl; carboxyl; CN; nitro; amino; polyhalomethyl; polyhalomethylthio; —S(═O) p R 6 ; C(═NH)R 6 ; R 2a is CN; amino; substituted amino; C 1-6 alkyl; halo; C 1-6 alkyloxy; carbonyl; —CH═N—NH—C(═O)—R 16 ; C 1-6 alkyloxyC 1-6 alkyl; C 2-6 alkenyl or C 2-6 alkynyl; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 or —X—R 7 ; R 3 is CN; amino; C 1-6 alkyl; halo; C 1-6 alkyloxy; substituted carbonyl; —CH═N—NH—C(═O)—R 16 ; substituted C 1-6 alkyl; C 1-6 alkyloxyC 1-6 alkyl; substituted C 2-6 alkenyl or C 2-6 alkynyl; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 ; —X—R 7 ; R 4 is halo; OH; C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; C 3-7 cycloalkyl; C 1-6 alkyloxy; CN; nitro; polyhaloC 1-6 alkyl; polyhaloC 1-6 alkyloxy; substituted carbonyl; formyl; amino; mono- or di(C 1-4 alkyl)amino or R 7 ; -A-B— is —CR 5 ═N—, —N═N—, —CH 2 —CH 2 —, —CS—NH—, —CO—NH—, —CH═CH—; and the use of these compounds for the prevention or the treatment of HIV infection.

Claims (9)

1. A compound of formula

wherein R 2a is cyano, R 3 is ethenyl substituted with cyano, R 4 is —CH 3 or halo, and -A-B— is a radical —N═N— (c-2), N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof.

2. A compound of claim 1 , selected from the group consisting of:

and

N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof.

3. A composition comprising: a therapeutically effective amount of

and a pharmaceutically acceptable carrier.

4. A process for preparing a composition as claimed in claim 3 , said process comprising mixing a compound selected from:

with the carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →
CHANGE OF NAME Recorded Jan 8, 2014
From: TIBOTEC PHARMACEUTICALS LTD.
To: JANSSEN R&D IRELAND
Reel/Frame 031918/0166 →